Switzerland buys access to potential Covid-19 treatment drug
The drug could also be administered to risk groups and those in front-line jobs, the Health Office said.
Keystone / Alessandro Crinari
The Swiss government has signed an agreement with a Zurich company for priority access to a drug being developed to treat those severely ill with Covid-19.
This content was published on
1 minute
Keystone-SDA/dos
Português
pt
A Suíça compra acesso ao potencial medicamento de tratamento para o Covid-19
The deal with the Molecular Partners firm gives Switzerland access to the first 200,000 doses of the medicine, as well as up to three million further doses when requested, the Federal Office for Public Health (FOPH) announcedExternal link on Tuesday.
The deal is worth several million francs, the Keystone-SDA news agency reported.
The immunotherapeutic agent, currently in development, is “comparable to mixtures of antibody therapies that are used to neutralise the virus”, the FOPH wrote. If approved, it would mainly be used to treat people already infected with Covid-19, although it could also be administered to risk groups as a prophylactic.
Clinical trials of the drug are planned for Autumn 2020.
The deal is another leg of the government’s anti-coronavirus strategy. It has also put aside CHF300 million ($329 million) for the procurement of a vaccine, and last week announced the pre-purchase of up to 4.5 million doses of a drug being developed by US firm Moderna.
Popular Stories
More
Multinational companies
Azeri fossil-fuel cash cow brings controversy to Switzerland
Swiss price watchdog slams excessive prices for generic medicines
This content was published on
The cheapest generic medicines available in Switzerland are more than twice as expensive as in other countries, according to a study by the Swiss price watchdog.
Nature should not figure in net zero calculations: academic study
This content was published on
The natural removal of CO2 from the atmosphere by forests or oceans should not be included in the net-zero balance of climate protection measures, argue researchers.
This content was published on
None of the 15 major Swiss retail banks is meeting international climate and biodiversity targets, according to a ranking by WWF Switzerland.
This content was published on
Nestlé's new CEO Laurent Freixe, has presented plans for the future of the world's largest food company, after his first few weeks in office.
Swiss foreign minister calls on Moscow to end Ukraine war
This content was published on
It's high time Moscow ended its war against Ukraine, Swiss foreign minister Ignazio Cassis tells the UN Security Council.
This content was published on
The only alternative to the UN Palestinian agency’s work in Gaza is to allow Israel to run services there, Philippe Lazzarini, UNRWA Commissioner-General, told reporters in Geneva on Monday.
Study reveals food culture differences between Switzerland and neighbours
This content was published on
Three-quarters of Swiss people consider eating to be a pleasurable, social activity, a new survey reveals. Healthy eating, however, plays a much less important role, it found.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Government earmarks CHF300 million to secure Covid-19 vaccine
This content was published on
The Swiss government is setting aside funds to procure enough doses of a Covid-19 vaccine for the country’s 8.6 million population.
Switzerland pre-orders 4.5 million doses of Covid-19 vaccine
This content was published on
The Swiss government has signed a deal with US biotech firm Moderna to secure early access to 4.5 million doses of a Covid-19 vaccine currently in development.
This content was published on
It’s the question we all want an answer to: when will there be a vaccine against Covid-19? And how is fair access being negotiated?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.